Domain Therapeutics and Chime Biologics News and Resources

Domain Therapeutics, a clinical-stage biopharmaceutical company, and Chime Biologics CDMO, have announced the signing of a manufacturing service agreement. The agreement is for the production of Domain’s best-in-class Treg depleting anti-CCR8 antibody candidate, DT-7012. This phase of manufacturing aims to deliver an